Split Tech City je zajednica sastavljena od tvrtki, udruga, institucija, meetupa i pojedinaca koji su posvećeni razvoju tehnološkog sektora u Splitu i regiji.Postani član
Datum objave: 27.2.2023.
Agilathon is the market leader in ePRO delivery expertise, leveraging a global team of consultants that are subject matter experts in: software design, validation, delivery, enablement, compliance, and operations.
Our mission is to ensure that therapeutics make it to the patients that need them, in the least amount of time and with the highest quality.
We transform the life sciences by scaling the study delivery capabilities of DCT vendors, CROs, and sponsors. With over 16 years of experience we are eCOA industry pioneers that deliver the best-in-class tech innovation services for decentralized clinical trials.
Partners leverage our expertise to ensure that their trials start on time and are executed with high quality. With over 1,200+ studies of experience, we enable our Partners to be transformational leaders in a competitive and fast-moving industry.
Our great team of 100+ engineers is made up of exceptionally talented and grounded humans. We’ve grown, but our company still feels intimate and our culture is deeply rooted in our values.
We are recognized as an exceptional place to work and grow. Thus we have our choice of team members. Our alumni take influential positions in the life sciences industry and remain active participants in our network for years to come.
We are based in two offices: The Croatian office is spread across two offices in Split and US office is based in Cambridge. We’ve been using the 6-hour difference between the two time-zones to our advantage, and over the years, created and perfected a well-defined process for maximizing our teams’ efficiency.
For each clinical study, we create a cross-functional team, with appropriate skills to handle the project size and complexity. We work closely with the client’s project management to identify the appropriate resources and prioritize the work against other concurrent studies.